10-K Filing

Oruka Therapeutics, Inc. CIK: 907654 FY 2024

Filing Information

Form Type	10-K
Accession Number	`0001213900-25-021165`
Period End Date	20241231
Filing Date	20250306
Fiscal Year	2024
Fiscal Period	FY
XBRL Instance	ea0230445-10k_orukathe_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 108 Income Statement 30 Cash Flow Statement 70 Stockholders Equity 40

Balance Sheet 108 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$61.58M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$61.58M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Marketable securities, current	`MarketableSecuritiesCurrent`	-	USD	Point-in-time
Marketable securities, current	`MarketableSecuritiesCurrent`	-	USD	Point-in-time
Marketable securities, current	`MarketableSecuritiesCurrent`	$314.07M	USD	Point-in-time
Marketable securities, current	`MarketableSecuritiesCurrent`	$314.07M	USD	Point-in-time
Subscription receivable	`SubscriptionReceivables`	-	USD	Point-in-time
Subscription receivable	`SubscriptionReceivables`	-	USD	Point-in-time
Subscription receivable	`SubscriptionReceivables`	$1.00K	USD	Point-in-time
Subscription receivable	`SubscriptionReceivables`	$1.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	-	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	-	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.22M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.22M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$376.87M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$376.87M	USD	Point-in-time
Common stock, par value (in Dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in Dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in Dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in Dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Marketable securities, long-term	`MarketableSecuritiesNoncurrent`	-	USD	Point-in-time
Marketable securities, long-term	`MarketableSecuritiesNoncurrent`	-	USD	Point-in-time
Marketable securities, long-term	`MarketableSecuritiesNoncurrent`	$18.07M	USD	Point-in-time
Marketable securities, long-term	`MarketableSecuritiesNoncurrent`	$18.07M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	545.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	545.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	65.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	65.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	37.44M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	37.44M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	3.20M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	3.20M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$162.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$162.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	-	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	-	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	-	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	-	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	37.44M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	37.44M	shares	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$876.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$876.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	3.20M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	3.20M	shares	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$43.00K	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$43.00K	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	-	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	-	USD	Point-in-time
Total assets	`Assets`	$1.00K	USD	Point-in-time
Total assets	`Assets`	$1.00K	USD	Point-in-time
Total assets	`Assets`	$396.02M	USD	Point-in-time
Total assets	`Assets`	$396.02M	USD	Point-in-time
Accounts payable	`AccountsPayableTradeCurrent`	$3.46M	USD	Point-in-time
Accounts payable	`AccountsPayableTradeCurrent`	$3.46M	USD	Point-in-time
Accounts payable	`AccountsPayableTradeCurrent`	-	USD	Point-in-time
Accounts payable	`AccountsPayableTradeCurrent`	-	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	-	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	-	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$3.35M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$3.35M	USD	Point-in-time
Operating lease liability, current	`OperatingLeaseLiabilityCurrent`	$213.00K	USD	Point-in-time
Operating lease liability, current	`OperatingLeaseLiabilityCurrent`	$213.00K	USD	Point-in-time
Operating lease liability, current	`OperatingLeaseLiabilityCurrent`	-	USD	Point-in-time
Operating lease liability, current	`OperatingLeaseLiabilityCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.04M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.04M	USD	Point-in-time
Operating lease liability, non-current	`OperatingLeaseLiabilityNoncurrent`	$755.00K	USD	Point-in-time
Operating lease liability, non-current	`OperatingLeaseLiabilityNoncurrent`	$755.00K	USD	Point-in-time
Operating lease liability, non-current	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Operating lease liability, non-current	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$13.80M	USD	Point-in-time
Total liabilities	`Liabilities`	$13.80M	USD	Point-in-time
Total liabilities	`Liabilities`	-	USD	Point-in-time
Total liabilities	`Liabilities`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively	`CommonStockValue`	$37.00K	USD	Point-in-time
Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively	`CommonStockValue`	$37.00K	USD	Point-in-time
Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively	`CommonStockValue`	-	USD	Point-in-time
Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively	`CommonStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$463.02M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$463.02M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-41.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-41.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-83.72M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-83.72M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$382.22M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$382.22M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$1.00K	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$1.00K	USD	Point-in-time
Total liabilities, convertible preferred stock and stockholders equity	`LiabilitiesAndStockholdersEquity`	$396.02M	USD	Point-in-time
Total liabilities, convertible preferred stock and stockholders equity	`LiabilitiesAndStockholdersEquity`	$396.02M	USD	Point-in-time
Total liabilities, convertible preferred stock and stockholders equity	`LiabilitiesAndStockholdersEquity`	$1.00K	USD	Point-in-time
Total liabilities, convertible preferred stock and stockholders equity	`LiabilitiesAndStockholdersEquity`	$1.00K	USD	Point-in-time

Income Statement 30 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$75.06M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$75.06M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$13.06M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$13.06M	USD	Annual
Total operating expenses	`OperatingExpenses`	$88.12M	USD	Annual
Total operating expenses	`OperatingExpenses`	$88.12M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-88.12M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-88.12M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$5.86M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$5.86M	USD	Annual
Interest expense	`InterestExpenseNonoperating`	$1.47M	USD	Annual
Interest expense	`InterestExpenseNonoperating`	$1.47M	USD	Annual
Other income, net	`OtherNonoperatingIncome`	$4.00K	USD	Annual
Other income, net	`OtherNonoperatingIncome`	$4.00K	USD	Annual
Total other income, net	`NonoperatingIncomeExpense`	$4.40M	USD	Annual
Total other income, net	`NonoperatingIncomeExpense`	$4.40M	USD	Annual
Net loss	`NetIncomeLoss`	$-83.72M	USD	Annual
Net loss	`NetIncomeLoss`	$-83.72M	USD	Annual
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-41.00K	USD	Annual
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-41.00K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-83.77M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-83.77M	USD	Annual
Net loss per share attributable to stockholders, basic (in Dollars per share)	`EarningsPerShareBasic`	$-3.87	USD	Annual
Net loss per share attributable to stockholders, basic (in Dollars per share)	`EarningsPerShareBasic`	$-3.87	USD	Annual
Net loss per share attributable to stockholders, diluted (in Dollars per share)	`EarningsPerShareDiluted`	$-3.87	USD	Annual
Net loss per share attributable to stockholders, diluted (in Dollars per share)	`EarningsPerShareDiluted`	$-3.87	USD	Annual
Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	16.79M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	16.79M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	16.79M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	16.79M	shares	Annual

Cash Flow Statement 70 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-83.72M	USD	Annual
Net loss	`NetIncomeLoss`	$-83.72M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$14.92M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$14.92M	USD	Annual
Net accretion of premiums and discounts on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$2.25M	USD	Annual
Net accretion of premiums and discounts on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$2.25M	USD	Annual
Non-cash interest expense	`OtherNoncashExpense`	$1.47M	USD	Annual
Non-cash interest expense	`OtherNoncashExpense`	$1.47M	USD	Annual
Non-cash lease expense	`OperatingLeaseExpense`	$127.00K	USD	Annual
Non-cash lease expense	`OperatingLeaseExpense`	$127.00K	USD	Annual
Depreciation expense	`Depreciation`	$27.00K	USD	Annual
Depreciation expense	`Depreciation`	$27.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.13M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.13M	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$43.00K	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$43.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInOtherAccountsPayable`	$3.46M	USD	Annual
Accounts payable	`IncreaseDecreaseInOtherAccountsPayable`	$3.46M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$3.29M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$3.29M	USD	Annual
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$-14.00K	USD	Annual
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$-14.00K	USD	Annual
Related party accounts payable and other current liabilities	`IncreaseDecreaseInAccountsPayableRelatedParties`	$6.02M	USD	Annual
Related party accounts payable and other current liabilities	`IncreaseDecreaseInAccountsPayableRelatedParties`	$6.02M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-57.84M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-57.84M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$189.00K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$189.00K	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$329.94M	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$329.94M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-330.13M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-330.13M	USD	Annual
Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid	`ProceedsFromIssuanceOfConvertiblePreferredStock`	$2.93M	USD	Annual
Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid	`ProceedsFromIssuanceOfConvertiblePreferredStock`	$2.93M	USD	Annual
Proceeds from issuance of notes payable to related party, net of issuance costs paid	`ProceedsFromNotesPayable`	$24.98M	USD	Annual
Proceeds from issuance of notes payable to related party, net of issuance costs paid	`ProceedsFromNotesPayable`	$24.98M	USD	Annual
Proceeds from the Pre-Closing Financing, net	`ProceedsFromPaymentsForOtherFinancingActivities`	$227.95M	USD	Annual
Proceeds from the Pre-Closing Financing, net	`ProceedsFromPaymentsForOtherFinancingActivities`	$227.95M	USD	Annual
Proceeds from the PIPE Financing, net	`ProceedsFromIssuanceOfPrivatePlacement`	$188.68M	USD	Annual
Proceeds from the PIPE Financing, net	`ProceedsFromIssuanceOfPrivatePlacement`	$188.68M	USD	Annual
Cash acquired in connection with the reverse recapitalization	`CashAcquiredInConnectionWithTheReverseRecapitalization`	$4.94M	USD	Annual
Cash acquired in connection with the reverse recapitalization	`CashAcquiredInConnectionWithTheReverseRecapitalization`	$4.94M	USD	Annual
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$54.00K	USD	Annual
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$54.00K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$449.54M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$449.54M	USD	Annual
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$61.58M	USD	Annual
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$61.58M	USD	Annual
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$61.58M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$61.58M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	-	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	-	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$61.58M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$61.58M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	-	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	-	USD	Point-in-time
Operating lease liability arising from obtaining operating right-of-use asset	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$982.00K	USD	Annual
Operating lease liability arising from obtaining operating right-of-use asset	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$982.00K	USD	Annual
Assets acquired in connection with the reverse capitalization	`NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1`	$114.00K	USD	Annual
Assets acquired in connection with the reverse capitalization	`NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1`	$114.00K	USD	Annual
Other liabilities assumed in connection with the reverse recapitalization	`NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1`	$54.00K	USD	Annual
Other liabilities assumed in connection with the reverse recapitalization	`NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1`	$54.00K	USD	Annual
Non-cash accrued interest on convertible note converted to common stock	`NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock`	$1.47M	USD	Annual
Non-cash accrued interest on convertible note converted to common stock	`NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock`	$1.47M	USD	Annual
Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock	`NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock`	$2.93M	USD	Annual
Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock	`NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock`	$2.93M	USD	Annual
Conversion of Series A non-voting convertible preferred stock to common stock	`ConversionOfStockAmountConverted1`	$52.83M	USD	Annual
Conversion of Series A non-voting convertible preferred stock to common stock	`ConversionOfStockAmountConverted1`	$52.83M	USD	Annual
Reclassification of the Paruka warrant from liability to equity	`ReclassificationOfTheParukaWarrantFromLiabilityToEquity`	$10.36M	USD	Annual
Reclassification of the Paruka warrant from liability to equity	`ReclassificationOfTheParukaWarrantFromLiabilityToEquity`	$10.36M	USD	Annual

Stockholders Equity 40 line items

Line Item	Tag	Value	Unit	Period
Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs	`IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts`	$69.00K	USD	Annual
Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs	`IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts`	$69.00K	USD	Annual
Balances	`StockholdersEquity`	$382.22M	USD	Point-in-time
Balances	`StockholdersEquity`	$382.22M	USD	Point-in-time
Balances	`StockholdersEquity`	$1.00K	USD	Point-in-time
Balances	`StockholdersEquity`	$1.00K	USD	Point-in-time
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	Annual
Issuance of common stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	Annual
Issuance of Series A convertible preferred stock, net of issuance costs of $69	`TemporaryEquityStockIssuedDuringPeriodValueNewIssues`	-	USD	Annual
Issuance of Series A convertible preferred stock, net of issuance costs of $69	`TemporaryEquityStockIssuedDuringPeriodValueNewIssues`	-	USD	Annual
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization	`TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$2.93M	USD	Annual
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization	`TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$2.93M	USD	Annual
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization	`StockIssuedDuringPeriodValueConversionOfUnits`	$26.45M	USD	Annual
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization	`StockIssuedDuringPeriodValueConversionOfUnits`	$26.45M	USD	Annual
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing	`IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos`	$248.46M	USD	Annual
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing	`IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos`	$248.46M	USD	Annual
Issuance costs of Pre-Closing Financing and reverse recapitalization	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$20.50M	USD	Annual
Issuance costs of Pre-Closing Financing and reverse recapitalization	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$20.50M	USD	Annual
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization	`IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe`	$5.00M	USD	Annual
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization	`IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe`	$5.00M	USD	Annual
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing	`IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr`	$144.44M	USD	Annual
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing	`IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr`	$144.44M	USD	Annual
Issuance costs of PIPE Financing	`IssuanceCostOfPIPEFinancing`	$-8.59M	USD	Annual
Issuance costs of PIPE Financing	`IssuanceCostOfPIPEFinancing`	$-8.59M	USD	Annual
Conversion of Series A non-voting convertible preferred stock to common stock	`ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock`	$52.83M	USD	Annual
Conversion of Series A non-voting convertible preferred stock to common stock	`ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock`	$52.83M	USD	Annual
Issuance of common stock under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$53.00K	USD	Annual
Issuance of common stock under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$53.00K	USD	Annual
Reclassification of the Paruka warrant from liability to equity	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$10.36M	USD	Annual
Reclassification of the Paruka warrant from liability to equity	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$10.36M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$4.56M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$4.56M	USD	Annual
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-41.00K	USD	Annual
Unrealized loss on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-41.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-83.72M	USD	Annual
Net loss	`NetIncomeLoss`	$-83.72M	USD	Annual
Balances	`StockholdersEquity`	$382.22M	USD	Point-in-time
Balances	`StockholdersEquity`	$382.22M	USD	Point-in-time
Balances	`StockholdersEquity`	$1.00K	USD	Point-in-time
Balances	`StockholdersEquity`	$1.00K	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.